Federal Circuit upholds schizophrenia drug ruling

16-04-2018

Vanda Pharmaceuticals, a biopharmaceutical company based in Washington, DC, secured a win late last week when the US Court of Appeals for the Federal Circuit found a patent covering its schizophrenia drug to be patentable.


Vanda Pharmaceuticals, West-Ward Pharmaceuticals, Hikma, US Court of Appeals for the Federal Circuit, patent infringement

LSIPR